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Abstract
Congenital cholesteatomas are epithelial lesions that present as an epithelial pearl behind
an intact eardrum. Congenital and acquired cholesteatomas progress quite differently from
each other and progress patterns can provide clues about the unique origin and pathogene-
sis of the abnormality. However, the exact pathogenic mechanisms by which cholesteato-
mas develop remain unknown. In this study, key proteins that directly affect cholesteatoma
pathogenesis are investigated with proteomics and immunohistochemistry. Congenital cho-
lesteatoma matrices and retroauricular skin were harvested during surgery in 4 patients
diagnosed with a congenital cholesteatoma. Tissue was also harvested from the retraction
pocket in an additional 2 patients during middle ear surgery. We performed 2-dimensional
(2D) electrophoresis to detect and analyze spots that are expressed only in congenital cho-
lesteatoma and matrix-assisted laser desorption/ionization time of flight mass spectrometry
(MALDI-TOF/MS) to separate proteins by molecular weight. Protein expression was con-
firmed by immunohistochemical staining. The image analysis of 2D electrophoresis showed
that 4 congenital cholesteatoma samples had very similar protein expression patterns and
that 127 spots were exclusively expressed in congenital cholesteatomas. Of these 127
spots, 10 major spots revealed the presence of titin, forkhead transcription activator homo-
log (FKH 5–3), plectin 1, keratin 10, and leucine zipper protein 5 by MALDI-TOF/MS analy-
sis. Immunohistochemical staining showed that FKH 5–3 and titin were expressed in
congenital cholesteatoma matrices, but not in acquired cholesteatomas. Our study shows
that protein expression patterns are completely different in congenital cholesteatomas,
acquired cholesteatomas, and skin. Moreover, non-epithelial proteins, including FKH 5–3
and titin, were unexpectedly expressed in congenital cholesteatoma tissue. Our data indi-
cates that congenital cholesteatoma origins may differ from those of acquired cholesteato-
mas, which originate from retraction pocket epithelia.
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Introduction
A congenital cholesteatoma is a keratinized squamous epithelial middle ear lesion that usu-
ally presents in young children who do not have a history of otitis media, middle ear surgery,
or trauma. The presentation and progress of congenital cholesteatoma are quite different
from those of acquired cholesteatoma. Congenital cholesteatomas commonly appear as
pearl-like epidermoid cysts, mostly located in the antero-superior quadrant behind an intact
tympanic membrane [1, 2]. These cholesteatomas can have invasive growth and cause osteo-
lysis [3].
The pathogenesis of congenital cholesteatomas seems to be different from acquired cho-
lesteatomas, which usually arise from the retraction pocket of the pars flaccida of tympanic
membrane and have attic destruction [4, 5]. Several pathogenic mechanisms of congenital
cholesteatoma have been suggested, including epithelial rests from faulty embryogenesis,
invagination or implantation of squamous epithelium, and metaplasia of middle ear epithe-
lium [6]. These suggested pathogenic mechanisms are based on temporal bone histology
studies [7–12]. There have been several studies that investigated differences in molecular
properties between congenital and acquired cholesteatomas. Upregulation of P21, shorter
telomere length, increased surviving expression, and absence of ICAM-1 expression and
LFA-1 positive cells have all been suggested to play a role in congenital cholesteatoma
pathogenesis. Unfortunately, their exact roles have not been fully identified [3–5, 13].
These studies investigated several target proteins, but no reports have identified differences
in molecular expression between congenital and acquired cholesteatoma by mass screening
of proteins in each tissue, largely because of the lack of an ideal animal model and a limited
number of specimens, which restricted basic molecular and biochemical research on congen-
ital cholesteatoma pathogenesis.
Here, we investigate differences in protein expression between congenital and acquired cho-
lesteatomas using proteomic analysis (for protein mass screening) and immunohistochemistry.
Our data suggest that protein expression patterns in congenital cholesteatomas are quite differ-
ent from those in acquired cholesteatomas and skin. The results of our study may provide clues
that allow for a better understanding of congenital cholesteatoma pathogenesis.
Materials and Methods
Tissue harvest
Patients were enrolled in this study after they or their parents provided written informed con-
sent. This study was approved by the institutional review board of Severance Hospital. Samples
of congenital cholesteatoma and retroauricular skin were harvested from 6 male children
between 4 and 5 year old. All congenial cholesteatomas presented as spherical epithelial pearls
behind an intact eardrum in the anterior superior quadrant (Fig 1). In all cases, the congenital
cholesteatoma was removed from the middle ear cavity without damaging its capsule. The tym-
panomeatal flap was elevated using the retroauricular approach. A small amount of retroauri-
cular skin (5 mm x 3 mm ellipsoid) was harvested as a control sample. Samples of acquired
cholesteatomas in the pars flaccida area of tympanic membrane were also harvested from 2
adult patients during tympanomastoid surgery (Table 1).
Four harvested samples (subject 1–4 in Table 1) were placed in a small tube, immediately
frozen in liquid nitrogen, and stored at-80°C until the time of experiment for proteomic analy-
sis. Two samples for immunohistochemistry (subject 5 and 6 in Table 1) studies were stored in
4% paraformaldehyde. All samples were gently washed with normal saline 3–4 times to remove
contaminated tissue and blood.
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Fig 1. A representative case of congenital cholesteatomas examined in this study (Patient 2 in
Table 1). A. Otoscopic tympanic membrane findings. B. Axial computed tomography image of the temporal
bone. C. Surgical findings. D. Congenital cholesteatoma specimen obtained in surgery (scale bar: 5mm).
doi:10.1371/journal.pone.0137011.g001
Table 1. Study subjects and specimen descriptions.
Subject No. Gender/age Specimen type Specimen description
1 Male/4 years CC and RAS 3.0 mm diameter epithelial pearl
2 Male/4 years CC and RAS 2.5 mm diameter epithelial pearl
3 Male/4 years CC and RAS 3.5 mm diameter epithelial pearl
4 Male/5 years CC and RAS 3.0 mm diameter epithelial pearl
5 Male/5 years CC and RAS 3.5 mm diameter epithelial pearl
6 Male/5 years CC and RAS 3.0 mm diameter epithelial pearl
5 Female/29 years AC 2 x 2 mm retraction pocket
6 Female /51 years AC 2 x 3 mm retraction pocket
AC, acquired cholesteatoma; CC, congenital cholesteatoma; RAS, retroauricular skin.
doi:10.1371/journal.pone.0137011.t001
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Sample preparation for 2-Dimensional Electrophoresis
Samples for 2-dimensional electophoresis (2-DE) were suspended in 4x sample buffer (7 M
urea, 2 M thiourea, 4% CHAPS, 0.5% ampholyte, 100 mM dithiothretol, 40 mM Tris, 0.002%
bromophenol blue) and sonicated. Then, 10μMDNase solution was added and the sample was
incubated for 30 minutes at 4°C. After incubation, samples were centrifuged (105,000 G) for 45
minutes. Next, 50% trichloroacetic acid (TCA; Sigma, St. Louis, MO, USA) was added to obtain
a final TCA concentration of 5–8%. Samples were then incubated for 2 hours on ice. After
incubation, 200 μL of cold acetone was added and the protein pellet was resuspended with a
pipette. Samples were again incubated on ice for 15 minutes and centrifuged (14,000 G) for 20
minutes, after which the acetone was discarded. Finally, the protein pellet was air-dried and
dissolved in 200 μL sample buffer for quantification with Bradford methods.
Two-Dimensional Electrophoresis
All 2-DE was performed as described [14]. Briefly, aliquots in sample buffer (260 μg) were
applied to immobilized pH 3–10 nonlinear gradient strips (Amersham Biosciences, Uppsala,
Sweden). Isoelectric focusing was performed at 80,000 Vh. The second dimension was analyzed
on 9–16% linear gradient polyacrylamide gels (18 cm × 20 cm × 1.5 cm) at a constant 40 mA
per gel for 5 hours. After protein fixation in 40% methanol and 5% phosphoric acid for 1 hour,
gels were stained with Coomassie Brilliant Blue G-250 for 12 hours. Gels were then destained
with H2O, scanned in a Bio-Rad GS710 densitometer (Bio-Rad, Hercules, CA, USA), and con-
verted into electronic files (12 bit tiff).
2-DE image analysis
Detection of individual spots and measurement of their volume (%) was performed with Image
Master Platinum 5 software (GE Healthcare, Piscataway, NJ). Protein spots exclusively identi-
fied in congenital cholesteatoma samples were analyzed.
Protein Identification with Mass Spectrometry
Among the exclusive spots identified by 2-DE image analysis, protein components of the 10
most prominent spots were investigated using matrix-assisted laser desorption/ionization time
of flight mass spectrometry (MALDI-TOF MS). For 2-DE gel mapping, major proteins were
identified by mass finger printing. Protein spots excised from 2-DE gels were destained,
reduced, alkylated, and digested with trypsin (Promega, Madison, WI), as previously described
[15]. For MALDI-TOF MS analyses, peptides were concentrated with a POROS R2, Oligo R3
column (Applied Biosystems, Foster city, CA, USA). After washing the column with 70% ace-
tonitrile, 100% acetonitrile, and 50 mM ammonium bicarbonate, samples were applied to the
R2, R3 column and eluted onto the MALDI plate (Opti-TOF 384-well Insert, Applied Biosys-
tems) with cyano-4-hydroxycinnamic acid (CHCA; Sigma, St. Louis, MO) dissolved in 70%
acetonitrile and 2% formic acid [16]. MALDI-TOF MS was performed on 4800 MALDI-TOF/
TOF Analyzer (Applied Biosystems) equipped with a 355 nm Nd:YAG laser. The pressure in
the TOF analyzer was approximately 7.6 x 10–7 Torr. Mass spectra were obtained in the reflec-
tron mode with an accelerating voltage of 20 kV, summed from 500 laser pulses, and calibrated
using the 4700 calibration mixture (Applied Biosystems). Proteins were identified from the
peptide mass maps using MASCOT (http://www.matrixscience.com/search_form_select.
html), which searched the 115,818 entries in the protein databases of the National Center for
Biotechnology Information (NCBI) non-redundant human database (downloaded on 05/09/
2009).
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Immunohistochemical staining
To confirm titin and FKH 5–3 protein expression in congenital cholesteatomas, tissues were
fixed with 4% paraformaldehyde for 24 hours, dehydrated, and embedded in paraffin. Paraffin
blocks were sectioned into 5 μm thick slices and fixed with a chilled 1:1 mixture of methanol:
acetone for 5 minutes after pretreatment with 0.3% H2O2 for 20 minutes at room temperature.
Slides were treated with 1:600 normal rabbit serum for 20 minutes to block nonspecific reac-
tions and then incubated with a polyclonal antibody against target human proteins, including
titin (1:200, HPA007042, Sigma, St. Louis, MO, USA) and forkhead transcription activator
homolog (1:200, clone FKH 5–3, human (fragment), AHP933, AbD Serotec, Kidlington,
England). Slides were then incubated with biotinylated antihuman rabbit immunoglobulin G
(1:200; Vector Laboratories, Burlingame, CA, USA). For negative controls, the step in which
samples were reacted with primary antibodies (titin and clone FKH 5–3) was skipped. Peroxi-
dase was attached to the secondary antibody by avidin-biotin peroxidase complex formation.
Specimens were incubated in diaminobenzidine tetrahydrochloride to detect primary antibody
binding sites.
Results
Differential protein expression in congenital cholesteatoma, acquired
cholesteatoma, and external canal skin
The 2-DE analysis of the four congenital cholesteatoma samples showed very similar protein
expression patterns (Fig 2) that were quite different from acquired cholesteatoma and retro-
auricular skin samples (Fig 3). A total of 556 spots were identified in congenital cholesteatomas
from 2-DE images analysis. Of the 556 spots, 270 were also simultaneously expressed in
acquired cholesteatoma and EAC skin. Additionally, 103 and 56 spots were expressed in skin
and acquired cholesteatoma, respectively. Finally, 127 spots were only expressed in congenital
cholesteatoma (Fig 4).
Main proteins expression in congenital cholesteatoma
The MALDI-TOF MS analyses were performed to identify the 10 most abundant spots (out of
127 spots) that were only expressed in congenital cholesteatoma (Fig 5). These proteins are
summarized in Table 2 and included titin (gi|407139), PRO2619 (gi|11493459), forkhead tran-
scription activator homolog (gi|477361, FHK 5–3), ryanodine receptor 2 isoform CRA_c (gi|
119590477), plectin 1 intermediate filament binding protein (gi|119602578), keratin 10 (epi-
dermolytic hyperkeratosis; keratosis palmaris et plantaris, gi|119581085), keratin 10 (gi|
186629), keratin 10 (gi|119581085), titin (gi|407139), and leucine zipper protein 5 isoform
CRA_b (gi|119624991).
Forkhead transcription factor (FKH 5–3) and titin expression in
congenital cholesteatoma
Among the proteins confirmed by MALDI-TOF MS, FKH 5–3 and titin proteins were selected
based on antibody availability and connection probability between previously described patho-
genesis and known protein characteristics. Immunolocalization demonstrated that FKH 5–3
and titin were localized in the cell membrane and cytoplasm in all layers of congenital choles-
teatoma keratinocytes (Fig 6).
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Discussion
Recent studies of cholesteatoma have focused on acquired cholesteatoma [1, 17, 18]. A rela-
tively small number of studies have been published on congenital cholesteatoma. To the best of
our knowledge, no prior studies have used proteomics to investigate congenital cholesteatoma
pathogenesis.
Our study showed that protein spot 2-DE distribution patterns of congenital cholesteatoma
are consistent among specimens and completely different from acquired cholesteatoma. Many
proteins (127 spots) were exclusively expressed in congenital cholesteatoma, and not found in
EAC skin or acquired cholesteatoma. Proteins that we did not expect to be expressed in fully
differentiated epithelial cells were titin (gi|407139), forkhead transcription activator homolog
Fig 2. Expression pattern of protein spots identified with 2-dimensional electrophoresis of congenital cholesteatoma. Expression patterns in the 4
patients examined were similar (A-D).
doi:10.1371/journal.pone.0137011.g002
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Fig 3. Protein expression patterns in congenital cholesteatoma (left), acquired cholesteatomas (middle), and the retroauricular canal skin (right).
doi:10.1371/journal.pone.0137011.g003
Fig 4. Venn diagram showing the number of identified protein spots in each tissue.One hundred
twenty seven spots were only expressed in congenital cholesteatoma.
doi:10.1371/journal.pone.0137011.g004
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(FKH 5–3, gi|477361), ryanodine receptor 2 (cardiac), and isoform CRA_c (gi|119590477), all
of which are expressed in mesodermal tissues [19–21].
Several theories have been proposed regarding congenital cholesteatoma origin, including
the ‘epithelial rest theory’ [10], the ‘invagination theory’ [22, 23], and the ‘implantation theory’
[9]. Although it remains unclear which theory best describes congenital cholesteatoma etiology,
all theories insist that congenital and acquired cholesteatoma have different origins. Aquired
cholesteatoma generally arise from a pars flaccida retraction pocket.
Unexpected expression of non-epithelial protein in our experiments contradicts the epithe-
lial rest theory where the congenital cholesteatoma arises from ectodermal derivatives from the
first epibranchial placode, as found in various vertebrates. Among the 10 most abundant pro-
teins exclusively expressed in congenital cholesteatoma tissues, FKH 5–3 was most interesting.
Fig 5. Tenmajor spots only expressed in congenital cholesteatoma, as determined by image
analysis.
doi:10.1371/journal.pone.0137011.g005
Table 2. 10 major protein exclusively expressed in congenital cholesteatoma.
Spot No. gi number Protein name Mr PI % coverage Matched peptide number
112 gi|407139 titin 524823 8.06 10 28
127 gi|11493459 PRO2619 58513 5.96 21 15
128 gi|477361 FKH 5–3 12861 10.06 66 5
132 gi|119590477 ryanodine receptor 2 (cardiac) isoform CRA_c 568496 5.69 10 28
272 gi|119602578 plectin 1 intermediate ﬁlament binding protein isoform CRA_c 290791 5.62 14 41
294 gi|119581085 keratin 10 63536 5.13 28 16
385 gi|186629 keratin 10 39832 4.72 31 10
447 gi|119581085 keratin 10 63536 5.13 30 16
535 gi|407139 titin 524823 8.06 11 29
587 gi|119624991 leucine zipper protein 5 isoform CRA_b 9456 11.70 72 8
Mr, nominal mass; FKH, forkhead transcriptional factor; PI, calculated PI value; %coverage, sequence coverage; matched peptide number, number of
mass values matched.
doi:10.1371/journal.pone.0137011.t002
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Expression of this protein was also confirmed in congenital cholesteatoma by immunohis-
tochemistry. Forkhead proteins, a family of transcription factors, play pathophysiologic roles
in regulating expression of genes involved in cell growth, proliferation, differentiation, and lon-
gevity. Forkhead proteins regulate embryonic development mechanisms [24] and are expressed
in hematopoietic stem cells that originate from the mesoderm and regulate lymphocyte devel-
opment [20]. It has also been reported that forkhead transcription factors can be a downstream
target of the Akt/PKB pathway, which is activated by microRNA 21 upregulation and subse-
quent apoptosis inhibition [25]. The presence of FKH 5–3 might indicate abnormal cell growth
and be the pathogenic origin of congenital cholesteatoma.
Another distinctive finding of our study was expression of titin in congenital cholesteatoma.
Titin is exclusively expressed in muscle [26] and originates from the mesoderm, where it plays
a key role in vertebrate striated muscle assembly and function. Recent studies also found that
titin is expressed in chromosomes and has functions related to oncogenesis [27–30]. We found
that titin matched the major spots found in proteomic analysis on congenital cholesteatoma
samples and was also strongly expressed in cholesteatoma matrices, as shown with immunos-
taining. The role of these proteins remain unclear in pathophysiology of congenital cholestea-
toma, but we suggest it may be involved in congenital cholesteatoma cell proliferation.
Although several markers indirectly suggest pathogenic mechanisms of congenital choles-
teatoma, our study has two main limitations. First, proteomics studies have inherent limita-
tions. The amount of expression was determined only by image analysis, which could have
differed if a more delicate experimental method was used. Therefore, there could be more
abundant proteins that exclusively exist in congenital cholesteatoma. In addition, we only
investigated the 10 most abundant spots identified in 2-DE analysis. However, there could be
more important proteins that play a larger role in congenital cholesteatoma pathogenesis. We
were only able to theorize congenital cholesteatoma pathogenic mechanisms using exclusive
protein expression found by proteomic analysis. However, no information was gained on the
role or importance of identified proteins in pathogenesis, which require animal models and/or
in vitro cell culture systems. Second, limitations arose from working with harvested tissue.
Fig 6. Expression of forkhead transcriptional factor homolog (FKH 5–3, A) and titin (B) in congenital cholesteatoma, as detected with
immunohistochemistry. Both proteins were well-expressed in cholesteatoma matrix. Negative controls (C, D) are also shown for comparison.
doi:10.1371/journal.pone.0137011.g006
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Congenital cholesteatoma tissue forms a cystic pearl, which was properly washed. Therefore,
there should have been little contamination from surrounding tissue. However, sample con-
tamination by middle ear mucosa cannot be completely excluded in acquired cholesteatoma
because acquired cholesteatomas are located in retraction pockets and strongly adhere to mid-
dle ear mucosa. There also could have been contamination with blood even though surface
blood was removed by extensive tissue washing (5–6 times in normal saline until blood no lon-
ger visible).
Even with these limitations, our proteomic study on congenital cholesteatoma tissue pro-
vides some clues on cholesteatoma pathogenesis. It is tempting to speculate that the origin of
congenital cholesteatomas differs from that of acquired cholesteatomas, which originate from
tympanic membrane epithelium. This study provides justification for future research on con-
genital cholesteatoma pathogenesis.
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